Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. reports developments for a commercial pharmaceutical business that markets differentiated products primarily in oncology. Company updates focus on product sales, commercial execution, portfolio changes, and financial results for its single reportable segment, including activity tied to Rolvedon and other branded pharmaceutical assets.
Recent announcements also cover capital-structure and corporate governance matters, material agreements, shareholder-related processes, and completed portfolio transactions. Assertio has reported the sale of U.S. rights to several branded products, including INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP, while continuing to frame its commercial strategy around oncology-focused products.
Assertio (Nasdaq: ASRT) agreed to be acquired by Zydus Worldwide DMCC via an all-cash tender offer at $23.50 per share, valuing the deal at about $166.4 million.
The price reflects premiums of 30.6% to the prior Garda deal and 75.8% to the unaffected March 20, 2026 close. Closing is expected in Q2 2026, with no financing contingencies or expected regulatory approvals, after which ASRT will be delisted from Nasdaq.
Assertio (Nasdaq: ASRT) and Garda reached a mutual agreement to delay the launch of the previously announced tender offer to May 14, 2026. Assertio reaffirmed its amended and restated merger agreement with Garda to be acquired for $21.80 per share, totaling $153.2 million in cash. The company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. Assertio also delayed the launch of the previously announced tender offer for all outstanding Convertible Senior Notes until May 14, 2026.
Assertio (Nasdaq: ASRT) and Garda mutually agreed to postpone the commencement of Garda's previously announced tender offer to acquire all outstanding Assertio shares to May 8, 2026. The Garda agreement values Assertio at $21.80 per share, or $153.2 million in total cash consideration. Assertio expects to file a Schedule 14D-9 on May 8, 2026. The company also postponed the tender offer for all outstanding Convertible Senior Notes until May 8, 2026.
Assertio (Nasdaq: ASRT) and Garda Therapeutics amended their merger agreement on May 1, 2026, raising the all-cash tender offer to $21.80 per share (≈$153.2M total). The revised price is a 21.1% increase from Garda’s prior offer and a 63.1% premium to the March 20, 2026 unaffected price. The transaction is expected to close in Q2 2026, requires a majority tender and will delist Assertio from Nasdaq upon completion. Assertio withdrew 2026 guidance and will file required SEC disclosures, including a Schedule 14D-9 and Form 8-K.
Assertio (Nasdaq: ASRT) and Garda agreed to extend the deadline to commence Garda’s tender offer to May 4, 2026. Assertio previously entered a definitive agreement for Garda to acquire all outstanding shares at $18.00 per share for total cash consideration of $125.1 million, plus a contingent value right. The Garda Agreement contains a 20-day window-shop allowing Assertio to solicit superior bids; if the board terminates for a superior bid during that period, a reduced breakup fee applies.
Assertio (Nasdaq: ASRT) said Garda Therapeutics intends to commence a tender offer to acquire all outstanding shares on April 29, 2026, after a 20-day window-shop period. The agreed purchase price is $18.00 per share, totaling $125.1 million in cash, plus a contingent value right. The window-shop permits Assertio to solicit superior bids; if the Board accepts a superior proposal and terminates the Garda Agreement, a reduced breakup fee would apply.
Cosette Pharmaceuticals closed an agreement to acquire U.S. sales and distribution rights for seven branded products from Assertio (Nasdaq: ASRT), adding a portfolio with $48.9 million in 2025 net sales. The deal includes SYMPAZAN® oral film, which establishes a Neurology rare disease footprint and carries patent protection through 2040.
The portfolio also includes INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® (OTREXUP was discontinued in Aug 2025). A transition period will move manufacturing, supply, quality, pharmacovigilance, and regulatory responsibilities to Cosette.
Assertio (Nasdaq: ASRT) agreed to be acquired by Garda Therapeutics for $18 per share in cash (total $125.1 million) plus a contingent value right (CVR) tied to Sprix milestones. The offer represents a 34.6% premium to the unaffected price and includes a 20-day window-shop period. Assertio also sold non-Rolvedon assets to Cosette for $35 million upfront plus earnouts. Closing is expected in Q2 2026, subject to a majority tender and customary conditions; Assertio stock will be delisted after closing.
Assertio (Nasdaq: ASRT) reported Q4 and full-year 2025 results and issued 2026 guidance. Full-year 2025 net product sales were $117.1M and Adjusted EBITDA was $22.7M. Rolvedon sales totaled $68.2M in 2025. Cash and short-term investments were $63.4M at year-end. For 2026 the company expects Net Product Sales $110M–$125M and Adjusted EBITDA $28M–$40M.
Q4 trends included a Rolvedon quarter‑end sell‑in that reduced Q4 Rolvedon sales and working capital variability into early 2026.
Assertio Holdings (Nasdaq: ASRT) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close.
Management will host a live webcast and earnings call at 4:30 p.m. Eastern Time; telephone dial-in and a webcast replay (available ~two hours after the call) are provided on the company investor website.